{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-26-000072","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2026-08-26T10:38:55+00:00","discovered_at":"2026-08-26T10:40:01.887284+00:00","generated_at":"2026-08-26T10:40:12.585524+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Biohaven licenses opakalim/Kv7 platform to SK Biopharmaceuticals for up to $795M","bullets":["SK Biopharmaceuticals licenses Biohaven's Kv7 platform led by opakalim, a Phase 2/3 selective Kv7.2/7.3 activator for focal epilepsy.","Biohaven receives $400M upfront ($350M at close, $50M in 2027) plus up to $150M development and regulatory milestones.","Tiered royalties on U.S. opakalim net sales range from mid-teens to low twenties; mid-single-digit on ex-U.S. net sales.","SKBP assumes up to $245M Knopp obligations: $185M on U.S./EMA approval of opakalim and up to $60M for future Kv7 programs.","Closing subject to antitrust clearance (HSR); RISE3 topline results expected in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-26-000072","json":"https://secwatch.observer/filing/0001935979-26-000072.json","markdown":"https://secwatch.observer/filing/0001935979-26-000072.md","text":"https://secwatch.observer/filing/0001935979-26-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/0001935979-26-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T10:40:12.585524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}